Victorians are one step closer to locally manufactured mRNA vaccines and medicines, with construction of Moderna’s mRNA vaccine manufacturing facility reaching the halfway mark, ahead of schedule.
On schedule for completion in 2024, Moderna’s manufacturing facility will have the capacity to produce 100 million vaccine doses per year for respiratory diseases including influenza, Respiratory Syncytial Virus (RSV), and COVID-19.
The construction phase has created up to 500 jobs and up to 500 additional advanced manufacturing jobs will be created once the facility is operational.
The manufacturing facility is a key component of Moderna’s strategic investment into Australia, complemented by the recent opening of Moderna’s Regional Research Centre for Respiratory Medicines and Tropical Disease and Moderna Headquarters for Australia, New Zealand, Southeast Asia and Oceania in Victoria.
Moderna is also forming partnerships with Victoria’s world-leading medical research institutes and clinical trial networks, allowing Victorians to be among the first people in the world to trial new mRNA medicines for a range of health conditions.
Victoria is responsible for almost 60% of Australia’s pharmaceutical exports – making it our highest-value advanced manufacturing export – and the biotech sector supports more than 100,000 full-time jobs.
